Formed at the University of California, Berkeley, NovaXS designed its patent-pending Telosis technology to administer a narrow stream of medication without a needle in 0.3 seconds and to analyze injection data to allow for smarter health decisions.
The company said in a news release that its technology represents the world’s first remote medication and self-administration monitoring platform as an easy and painless alternative for at-home drug delivery. The first indication being pursued by NovaXS is IVF treatments.
NovaXS presented its prototype at mHub’s MedTech Accelerator Program’s annual Demo Day in Chicago last week. COO and co-founder Jonathan Xing also shared the company’s plans for product development, market potential and revenue generation at the event, while highlighting milestones including submitting the new prototype for a patent and signing multiple letters of intent with IVF clinics in California.
The company was selected among hundreds of applicants based on its ability to address large, unmet needs with innovative solutions that will transform patient care, the company said.
“NovaXS’ team has been working hard to develop a user-friendly no-needle solution for injection drug delivery. We envision a day when people living with chronic illness have one less thing to worry about because all they have to do to administer their medication is press one button and their healthcare provider can remotely monitor their treatment,” Xing said. “mHub’s accelerator program has given NovaXS the tools and resources we need to focus on product development and has provided opportunities for us to connect with new investors and industry partners.”
